Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4644 First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,

#4622 Elucidating the role of high mobility group box 3 (Hmgb3) during progression and response to radiation therapy in pancreatic neuroendocrine tumours

Introduction: We have recently demonstrated that HMGB3 is upregulated during the pancreatic neuroendocrine tumours (PanNETs) transition via dedifferentiation from a relatively benign molecular subtype to an aggressive and highly metastatic molecular subtype. HMGB3 expression has recently been linked to resistance to therapy, metastasis, and poor prognosis in patients with various solid cancers.

Conference:

Presenting Author: Kulathunga N

Authors: Kulathunga N, Wang Z, Qureshi A, Lok B, Tyryshkin K,

Keywords: pancreatic neuroendocrine tumour, HMGB3, tumour progression,

#4076 Machine learning model: Predicting prognosis in neuroendocrine tumors

Introduction: Neuroendocrine tumors (NETs) have a heterogeneous clinical course. Even with similar Ki-67 proliferative index/morphology, the course varies in patients with similar pathological characterization.

Conference:

Presenting Author:

Authors: Varghese D, Naimian A, Yazdian P, Lokre O, Perk T,

Keywords: Neuroendocrine tumor, artificial intelligence, DOTATATE scan,

#3191 Determination of somatostatin receptors types 2A and 5 (SSTR-2A, SSTR-5) expression in neuroendocrine tumors (NETs) and neuroendocrine carcinoma (NECs) of various localizations and grade

Introduction: One of the main treatment options for this disease is SA,which bind SSTRs to the on the surface of neuroendocrine cells (NC) and block them.But SSTRs are not always present in NC

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Emelianova G, Artamonova E, Ushakov A, Delektorskaya V, Markovich A,

Keywords: neuroendocrine tumor, neuroendocrine carcinoma, somatostatin receptor,

#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia

Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Gorbunova V, Orel N, Emelianova G,

Keywords: neuroendocrine tumors, everolimus, uni- and multivariate analysis,